HIV Management Guide for Clinical Care and ARV Guidelines

HIV Management Guide for Clinical Care and ARV Guidelines

Management

Initiation of antiretroviral therapy in the treatment-naïve patient

Mark Bloch1, Craig Rodgers2 Holdsworth House Medical Practice and East Sydney Doctors, Sydney NSW St Vincent’s Hospital, Sydney NSW Last reviewed: March 2016 Next review due: December 2019 Initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) in the naïve patient centres around two main questions: When to start therapy and what to therapy …

Initiation of antiretroviral therapy in the treatment-naïve patient Read More »

Antiretroviral treatment strategies

Acute or primary HIV infection Improved recognition of the clinical syndrome suggestive of acute HIV or primary HIV infection combined with use of newer diagnostic tests enables early identification of this group of individuals and thus consideration of antiretroviral therapy. The SPARTAC study randomised patients with primary HIV infection to 48 weeks vs 12 weeks …

Antiretroviral treatment strategies Read More »

References

The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795-807  The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015;373:808-22  Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection …

References Read More »

Antiretroviral drugs

Nicholas Medland1, Vincent Cornelisse2, Don Smith3 The Kirby Institute, University of NSW, Sydney, NSW Kirketon Road Centre, Sydney, NSW The Albion Centre, Surry Hills, Sydney, NSW Last reviewed: November 2019 Antiretroviral drug classes The six classes of antiretroviral drugs currently licensed for use in Australia are: Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs); Non-nucleoside reverse transcriptase inhibitors …

Antiretroviral drugs Read More »

Recommended regimens for treatment of HIV infection

The four regimens currently recommended for the initial treatment of most people with HIV infection combine a two-drug NRTI backbone with a third antiretroviral drug from the INSTI class, as follows: Dolutegravir/abacavir/lamivudine (if HLA-B*5701 negative) Dolutegravir + emtricitabine/tenofovir alafenamide (tenofovir AF) or tenofovir disoproxil fumarate (tenofovir DF) Raltegravir + emtricitabine/tenofovir AF or tenofovir DF Bictegravir/emtracitabine/tenofovir AF …

Recommended regimens for treatment of HIV infection Read More »

Nucleoside and nucleotide reverse transcriptase inhibitors

NRTIs inhibit HIV RNA-dependent DNA polymerase (reverse transcriptase) by acting as structural analogues for thymidine or adenosine when DNA is reverse transcribed inside cells leading to premature DNA chain termination and inhibition of viral replication.  All NRTIs also have the potential to inhibit human intracellular DNA polymerases, including those necessary for mitochondria to replicate. Mitochondrial …

Nucleoside and nucleotide reverse transcriptase inhibitors Read More »

Non-nucleoside reverse transcriptase inhibitors

The NNRTI class includes nevirapine (NVP), efavirenz (EFV), rilpivirine (RPV), etravirine (ETR) and doravirine (DOR). NNRTIs bind directly to the reverse transcriptase enzyme and block the RNA-dependent and DNA-dependent polymerase activities by causing a disruption of the enzyme’s catalytic site. This reduces enzyme activity and diminishes viral replication. Importantly NNRTIs are not active against HIV-2 …

Non-nucleoside reverse transcriptase inhibitors Read More »

Scroll to Top